Latest Guardant Health News & Updates

See the latest news and media coverage for Guardant Health. We track all announcements, press releases, and industry mentions in real time, all in one place.

Guardant Health

Blood-based precision oncology company

guardanthealth.com

Headquarters: Palo Alto, United States
Founded year: 2012
Company type: Public company
Number of employees: 4,500–5,000

Last updated Today

Latest news about Guardant Health

In short: Guardant Health achieved several FDA approvals and guideline inclusions while facing an $83 million patent litigation loss.

Company announcements

June 11 Guardant Health

Guardant Health's Guardant360 CDx approved for HER2-mutant NSCLC

The FDA cleared it as a companion diagnostic for Boehringer Ingelheim's targeted therapy as initial treatment.

June 3 Guardant Health

Guardant Health introduces Talent Communities to build future-ready networks

The initiative aims to keep candidates informed about purpose-driven opportunities and advance the mission to conquer cancer.

May 28 Guardant Health

Guardant Health presents 38 abstracts at ASCO 2026

The abstracts highlight methylation-based tumor classification, liquid biopsy advances, and the InfinityAI platform’s expanding clinical utility.

May 27 Guardant Health

Guardant Health announces Shield™ included in ACS guidelines

The ACS lists Shield™ as a blood-based colorectal screening option, noting it can expand access and help reach over 50 million unscreened Americans.

Media coverage

June 17 CancerNetwork

FDA OKs Updated Guardant360 Liquid CDx with Expanded Molecular Profiling | CancerNetwork

The FDA has approved the new Guardant360 Liquid CDx, an updated blood-based cancer test designed to support treatment selection in patients with advanced cancer, according...

June 17 Bloomberg Law

Guardant Loses Bid to Undo $83 Million DNA-Tech Patent Verdict

Guardant Health Inc. failed to overturn an $83.4 million DNA-sequencing patent verdict and must pay a 6% ongoing royalty to TwinStrand Biosciences Inc. and the...

June 11 Business Wire

Guardant Health Announces FDA Approval of Guardant360 CDx as Companion Diagnostic for Boehringer Ingelheim’s HERNEXEOS®

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guard...

May 28 Business Wire

American Cancer Society Recommends Guardant Health’s Shield Blood Test in Updated Colorectal Cancer Screening Guidelines

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that its FDA-approved Shield™ blood test is now included in updated Ameri...

Never miss news about Guardant Health

Track Guardant Health and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Guardant Health competitors & trending companies

Browse news for competitors to Guardant Health and other trending companies.